Does tenofovir alafenamide fumarate tablets (Vemlidy) need to be taken for life?

Tenofovir alafenamide fumarate tablets (Vemlidy/Vemlidy) is a new hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor, which is widely used in the treatment of chronic hepatitis B in adults and children over 12 years old, especially for patients with compensated liver disease. Tenofovir alafenamide tablets clinically inhibit viral replication and effectively reduce the viral load in the blood, thereby reducing the risk of liver inflammation and fibrosis.

As to whether lifelong medication is required, existing guidelines and clinical practice show that The characteristics of HBV infection determine that most patients may require long-term or even lifelong medication. Once the chronic hepatitis B virus enters the liver cells and forms cccDNA, it is difficult to completely eliminate it. Therefore, even if the virus level in the blood continues to decrease, drug withdrawal may still lead to virus rebound or liver function fluctuations. Clinical data show that early discontinuation of the drug may cause serological rebound and increase the risk of acute hepatitis and liver function damage, especially for patients with HBeAg negative or severe liver fibrosis.

However, whether to take it for life requires a comprehensive assessment of the patient's individual situation, including viral load, liver function indicators, liver fibrosis degree and previous antiviral treatment response. For some patients, under strict monitoring, when the virus is undetectable for a long time and the liver function is stable, doctors may try to reduce the dose or discontinue the drug, but follow-up and close observation are still required to detect recurrence in a timely manner. In other words, the long-term treatment of tenofovir alafenamide fumarate tablets is not only due to the characteristics of the drug, but also due to the chronic nature of HBV infection.

In addition, long-term use of tenofovir alafenamide fumarate tablets is generally well tolerated clinically, with high drug safety and relatively low adverse events related to renal function and bone density, making it an antiviral regimen suitable for long-term maintenance. Patients should regularly monitor liver function, viral load and renal function during use, and adjust treatment strategies according to doctor's recommendations to ensure continued antiviral effects while reducing potential risks.

Reference materials:https://www.vemlidyhcp.com/